Structure Therapeutics Inc. (GPCR) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $43.30: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 4.79; Below-average business quality.
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for obesity; lead candidate aleniglipron completed Phase 2b ACCESS program showing up to 11.3% placebo-adjusted weight loss at 36 weeks, with Phase 3 planned H2... Read more
Sell if holding. Engine safety override at $43.30: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 4.79; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 67. Score 5.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst cluster(8), earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Structure Therapeutics Inc.
Latest news
- NEWS Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday — benzinga Jun 11, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70 — benzinga Jun 11, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga Jun 8, 2026 neutral
- NEWS Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Ph — benzinga Jun 5, 2026 positive
- NEWS Structure Therapeutics Announces Publication Of Phase 2b Data For Obesity Treatment Aleniglipron, Phase 3 Trial Expected — benzinga Jun 5, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinealeniglipron10-K Item 1: 'Our most advanced product candidate to date is aleniglipron ... currently in five ongoing clinical studies for the treatment of obesity, overweight and related conditions'
Material Events(8-K, last 90d)
- 2026-04-15Item 5.02LOWMatthew Lang appointed as Chief Operating Officer and General Counsel effective April 15, 2026. Previously CLO/Corporate Secretary at Metsera (2025-2026) and CBO/CLO at Lyell Immunopharma (2023-2025).SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $43.30: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 4.79; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 67. Prior stop was $40.27. Score 5.4/10, moderate confidence.
Take-profit target: $95.82 (+121.3% upside). Prior stop was $40.27. Stop-loss: $40.27.
Concentration risk — Pipeline: aleniglipron; Quality below floor (1.5 < 4.0).
Structure Therapeutics Inc. trades at a P/E of N/A (forward -21.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover GPCR with a consensus score of 4.3/5. Average price target: $106.
What does Structure Therapeutics Inc. do?Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for...
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for obesity; lead candidate aleniglipron completed Phase 2b ACCESS program showing up to 11.3% placebo-adjusted weight loss at 36 weeks, with Phase 3 planned H2 2026. Pre-revenue; net loss was $141.2M in 2025 with $470.3M accumulated deficit; funded through equity with ~$191.5M remaining under ATM as of Dec 2025.